Can Dextromethorphan Cause a False Positive?

Dextromethorphan, the cough suppressant found in dozens of over-the-counter cold medicines, can trigger a false positive on certain drug tests. The most reliably documented problem is with phencyclidine (PCP) screens, where DXM is one of the leading causes of unconfirmed positives. The picture with opiate screens is more complicated and depends heavily on dose. Whether a standard dose of cough syrup could actually cause you to fail a drug test is a narrower question than most people realize, and the honest answer involves understanding which drug is being screened for and how much DXM is in your system.

PCP Screens Are the Main Vulnerability

The false-positive problem people worry about most with DXM is opiates, because the two molecules look similar on paper. But the strongest and most consistent evidence points in a different direction: PCP. Multiple studies and reviews have identified dextromethorphan as a well-known cause of false-positive phencyclidine results on immunoassay urine drug screens.¹ This is the cross-reactivity that labs and toxicologists have flagged for years, and it shows up reliably in clinical data.

A study examining PCP-positive urine screens that failed confirmatory testing found that roughly a quarter of those false positives came from patients who had documented dextromethorphan use. Among the 88 patients whose initial PCP screen came back positive but whose confirmatory test showed no actual PCP, about 24% had taken DXM. By comparison, tramadol accounted for about 22% and diphenhydramine (the antihistamine in Benadryl) about 15%.² DXM was the single most common medication linked to a false PCP positive in that sample. That is a striking number for something you can buy off a pharmacy shelf without a prescription.

A broader review of commonly prescribed and nonprescription medications confirmed dextromethorphan’s place on the list of drugs known to cause false-positive PCP results during urine screening.³ This is not a theoretical concern or an isolated case report. It happens regularly enough that emergency physicians and toxicologists consider it part of standard differential diagnosis when a PCP screen comes back positive.

Opiate False Positives Depend on How Much You Took

DXM is a synthetic compound derived from the same chemical family as morphine and codeine. That structural resemblance is why people assume it would trip an opiate screen. But research on this question has consistently shown that normal doses of cough medicine are unlikely to cause the problem. A study examining the standard EMIT opiate immunoassay found that a single normal dose or even twice the normal dose of dextromethorphan did not produce a false positive within six hours.⁴ The same review in Laboratory Medicine concluded that despite the structural similarities, studies show DXM does not cause a false positive for opiates at typical doses.¹

The story changes at higher doses. A 2025 case report and laboratory analysis found that high-dose dextromethorphan ingestion could produce a false-positive opiate screen on certain immunoassay platforms. The researchers spiked drug-free urine samples with DXM and its metabolite dextrorphan at various concentrations and found that a subset of commercially available opiate screening assays were susceptible to cross-reactivity at high concentrations.⁵ This matters because recreational misuse of DXM at doses far above what a cough-medicine label recommends does occur. At those levels, both PCP and opiate screens can be affected.

So the practical answer has two layers. If you took a recommended dose of cough syrup before a drug test, you are very unlikely to fail an opiate screen. If someone took a very large amount of DXM, especially at recreational-misuse levels, the risk of a false-positive opiate result becomes real, though it still varies by which brand of test kit is used.

Why Screening Tests Make These Mistakes

The initial drug tests used in most workplace, clinical, and forensic settings are immunoassays. These tests work by using antibodies designed to bind to a target molecule. The problem is that antibodies are not perfectly selective. If another molecule is shaped similarly enough, it can bind to the same antibody and produce a signal that the test reads as positive. This is called cross-reactivity, and it is the fundamental reason false positives happen with any immunoassay.

Dextromethorphan’s molecular structure shares enough geometry with PCP that PCP-targeted antibodies sometimes grab onto it. The opiate cross-reactivity is less consistent, which makes sense: DXM is related to opioids but is not actually an opiate in the traditional sense, so the degree of structural overlap with the antibody target varies depending on which specific antibody the test manufacturer chose. Different test kits from different manufacturers use different antibodies, and some are more prone to DXM cross-reactivity than others. That is why the 2025 laboratory study found that only a subset of commercially available opiate assays were affected.⁵

This variability between test platforms is something most people do not think about. The cheap rapid test strip your employer uses at a walk-in clinic might behave differently from the immunoassay a hospital laboratory runs on an automated analyzer. Both are screening tests, but they can have different antibody formulations and different cutoff thresholds. A false positive on one platform does not mean every platform would give the same result.

Confirmatory Testing Clears It Up

Any reputable drug-testing program treats a positive immunoassay screen as a preliminary result, not a final answer. The standard follow-up is confirmatory testing using either gas chromatography-mass spectrometry (GC/MS) or liquid chromatography-mass spectrometry (LC/MS). These methods identify individual molecules by their unique chemical fingerprint, not by antibody binding. They can distinguish DXM and its metabolites from PCP, morphine, codeine, or any other target drug with a high degree of accuracy.

This is the safety net that is supposed to catch every false positive. And in clinical and forensic labs that follow standard protocols, it generally works. The study of PCP false positives described earlier specifically identified its false-positive group as patients whose initial immunoassay screens were positive but whose confirmatory tests came back negative.² Confirmatory testing caught the error every time.

The catch is that not every testing situation includes confirmatory testing. Some employers use point-of-care rapid tests and act on the result without sending the sample for confirmation. Emergency departments sometimes make clinical decisions based on a rapid urine screen before confirmatory results are available, which can take hours or days. In those situations, a false positive from DXM could affect real decisions about your care or your employment before anyone has a chance to sort out what actually happened.

What to Do If You Are Facing a Drug Test

If you have a scheduled drug test coming up and you are taking an over-the-counter cough medicine containing dextromethorphan, the risk of a false positive on an opiate screen at standard doses is low. But the risk of a false-positive PCP result is real enough to take seriously, especially if you have been taking higher or more frequent doses than the label recommends.

A few practical steps can protect you:

Disclose your medications: Most workplace and clinical drug testing programs ask you to list any medications you are taking before the test. Including your cough medicine on that list creates a record that a medical review officer can use to evaluate a suspicious result.
Keep the packaging: If you get called about a positive screen, being able to show exactly which product you took and when you took it helps the medical review officer make a judgment.
Request confirmatory testing: If you receive a positive result and you believe it is a false positive, you have the right in most regulated testing programs to request that the sample be sent for GC/MS or LC/MS confirmation. Do not accept a screening result as final without confirmation.
Consider timing: If the test is not urgent and you can stop taking the cough medicine a few days beforehand, DXM and its metabolites clear from urine relatively quickly. Most of the drug is eliminated within 24 to 48 hours, though individual metabolism varies.

The “dextromethorphan defense” is a phrase that shows up in toxicology literature, referring to people who claim a positive drug test was caused by cough medicine.⁴ Research has tested that claim directly, and the conclusion is that it holds up poorly for opiate screens at normal doses but is genuinely plausible for PCP screens. If someone tells a medical review officer that their PCP positive was caused by cough syrup, the science actually supports that explanation in many cases.

DXM Is Not the Only Over-the-Counter Culprit

Dextromethorphan gets a lot of attention for false positives because it is in so many cold and flu products, but it is hardly the only common medication on the list. A review of formulary and nonprescription medications found false-positive reports associated with ibuprofen, naproxen, diphenhydramine, doxylamine, ranitidine, and even nonprescription nasal inhalers, among others. The most commonly reported false positives involved amphetamine and methamphetamine screens, though false positives for opioids, PCP, cannabinoids, barbiturates, and benzodiazepines also appeared.³

Diphenhydramine, the active ingredient in Benadryl and many nighttime cold formulas, was the second most common medication associated with false-positive PCP screens in the same study that identified DXM as the leader.² Many combination cold medicines contain both DXM and diphenhydramine, which means taking a single product like NyQuil could expose you to two different compounds, each independently capable of triggering a false PCP result. That stacking effect is something most people would not think about.

Prescription medications have their own false-positive profiles. Bupropion (commonly prescribed for depression and smoking cessation), venlafaxine (another antidepressant), sertraline, quetiapine, and trazodone have all been reported to cause various false positives.³ The broader takeaway is that immunoassay screening is a blunt tool. It is designed to be sensitive enough to catch real drug use, and the tradeoff for that sensitivity is that it inevitably catches some things that are not drug use at all.

When the Test Kit Matters More Than the Drug

One underappreciated dimension of this problem is how much the specific brand and generation of immunoassay matters. Laboratories do not all use the same test. The major clinical chemistry platforms, made by companies like Abbott, Siemens, Roche, and Beckman Coulter, each have their own antibody formulations for each drug class. A DXM concentration that triggers a false positive on one manufacturer’s PCP assay might not trigger it on another’s.

The 2025 cross-reactivity study made this point explicitly by testing multiple commercially available opiate screening assays against DXM and dextrorphan (DXM’s main metabolite). Only a subset of the assays they tested showed cross-reactivity, even at high concentrations.⁵ This means the answer to “can DXM cause a false positive for opiates” partly depends on which machine the lab happens to be running. You have no way of knowing that in advance, which is frustrating, but it also means that a false positive from one test does not prove you would fail every test.

For PCP, the cross-reactivity appears to be more widespread across platforms. The consistency of PCP false-positive reports across multiple studies and clinical settings suggests that DXM’s structural overlap with PCP is recognized by a broader range of PCP-targeted antibodies than its overlap with opioid-targeted antibodies. This is why the PCP false positive is the one toxicologists treat as an expected artifact rather than an unusual event.

DXM Products You Might Not Realize Contain It

Part of the practical challenge is that dextromethorphan shows up in an enormous range of products, and many people take it without realizing they are taking a compound that could interfere with a drug test. It is the “DM” in Robitussin DM, Mucinex DM, Delsym, Theraflu, and many store-brand equivalents. But it also appears in combination products where the marketing emphasizes a different ingredient: multi-symptom cold and flu formulas, some sore throat lozenges, and even certain liquid-filled capsules that people think of as “just decongestants.”

If you are subject to regular drug testing for any reason, it is worth reading ingredient labels on cold medicines before you buy them. Guaifenesin (an expectorant) and pseudoephedrine or phenylephrine (decongestants) do not carry the same false-positive risk profile. You can treat a cough or cold with products that do not contain DXM, and doing so eliminates this particular source of concern entirely. Your pharmacist can point you to alternatives if you are unsure.

One more thing worth knowing: DXM is now an active ingredient in a prescription medication approved for a neurological condition, sold under the brand name Nuedexta (combined with quinidine). Patients taking that medication are getting regular, sustained DXM exposure at therapeutic doses and should be aware that it could interact with any immunoassay screening they undergo. The same disclosure and confirmatory-testing principles apply, but the ongoing nature of the exposure makes advance communication with testing programs more important than it would be for someone who took a single dose of cough syrup.

1
Laboratory Medicine. Is Dextromethorphan a Concern for Causing a False Positive During Urine Drug Screening?
2
PubMed Central. How Often Do False-positive Phencyclidine (PCP) Urine Screens Occur with Use of Common Medications?
3
American Journal of Health-System Pharmacy. Commonly prescribed medications and potential false-positive urine drug screens
4
PubMed. The dextromethorphan defense: dextromethorphan and the opioid screen
5
PubMed. Cross-reactivity of urine opiates screening assays with dextromethorphan